News

• In September 2022, Aplexis was awarded a Phase I SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) to develop first-generation Plek2 inhibitors.
• In May 2023, Aplexis was selected as one of the ten biotech startups to showcase our therapeutic research in MPNs at the third annual Science2Startup (S2S) Symposium in Cambridge, Massachusettes.